Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P208 | ISIN: US68622P1093 | Ticker-Symbol: 4TZ
Frankfurt
24.04.25
16:02 Uhr
4,500 Euro
-0,320
-6,64 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
ORIC PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ORIC PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,5204,58016:21
4,5404,60016:21

Aktuelle News zur ORIC PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.04.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)103SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
► Artikel lesen
25.03.ORIC Pharmaceuticals: ORIC Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting1
20.03.Oric Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
14.03.Oric Pharmaceuticals, Inc. - 8-K, Current Report3
07.03.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)149SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
► Artikel lesen
25.02.ORIC Pharmaceuticals: ORIC Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones103Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ORIC-944 initiation of first Phase...
► Artikel lesen
25.02.Oric Pharmaceuticals, Inc. - 8-K, Current Report-
ORIC PHARMACEUTICALS Aktie jetzt für 0€ handeln
18.02.ORIC Pharmaceuticals: ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates112Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical...
► Artikel lesen
18.02.Oric Pharmaceuticals, Inc. - 10-K, Annual Report1
18.02.Oric Pharmaceuticals, Inc. - 8-K, Current Report-
18.02.Stifel maintains $20 target on ORIC shares, reiterates Buy rating2
11.02.ORIC Pharmaceuticals stock target holds at $21 by H.C. Wainwright1
10.02.Jones Trading maintains Buy on ORIC, $17 target on positive data2
10.02.Cantor Fitzgerald maintains Overweight on ORIC stock2
10.02.ORIC Pharmaceuticals shares surge on potential data leak2
10.02.ORIC Pharmaceuticals-Aktien steigen aufgrund möglicher Datenlecks2
07.02.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)145SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
► Artikel lesen
04.02.Cantor Fitzgerald maintains Overweight on ORIC shares, sees upside2
14.01.ORIC Pharma Stock Climbs On Clinical Supply Deal With J&J's Janssen For ORIC-1145
13.01.ORIC Pharmaceuticals: ORIC Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones119Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC Entered into clinical trial collaboration...
► Artikel lesen
Seite:  Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1